Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsStriatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movementsLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentPost- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Neuroproteomics as a promising tool in Parkinson's disease research.Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian ratsModeling Parkinson's disease in primates: The MPTP modelSubstantia nigra vulnerability after a single moderate diffuse brain injury in the rat.Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.Clinical aspects and management of levodopa-induced dyskinesia.Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.How should we treat a patient with early Parkinson's disease?Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsEmerging drugs for levodopa-induced dyskinesia.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias.Non-human primate models of PD to test novel therapies.Identification of genes associated with paraquat-induced toxicity in SH-SY5Y cells by PCR array focused on apoptotic pathways.Levodopa-induced ocular dyskinesias in Parkinson's disease.Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent regionally selective, bimodal effects on striatal dopamine kinetics in vivo.Novel observations with FDOPA-PET imaging after early nigrostriatal damage.Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
P2860
Q21129423-33EEDF97-3EB4-4B2C-9FAD-B96A5012C8B9Q24632752-7FE06C9E-42CA-41F3-B508-238C22DE6461Q24647141-A51E166F-8A77-4FF2-BB5C-4A01754B1BD5Q33255884-BF2AFE9E-CEBD-4132-B589-0CC8990496A1Q33821316-835BE112-57C0-4960-863F-66E2F191C2F7Q33872463-3388D3A3-189A-4A9B-890F-0CB47B37551EQ33917299-AA9BA3AF-2200-4553-87CD-72864A3F5E58Q35765748-302A3CDF-91E8-4CD8-8ACB-A3D014FC4D3AQ35803795-38DF66D9-5348-44FE-8A6F-166A53155D1BQ35932567-508C40D7-6DC9-4E8D-B3FD-23107A1BD6CCQ36022700-E9D34CBA-3C97-4764-A798-71542CB6A694Q37132571-83C0EFD9-8774-4676-9172-248D0F69FB62Q37398168-F4B47BBE-F5FD-4EE6-9839-CEC2CF4B0329Q37775098-08F1DDD3-7EBB-4EB9-BA48-6720BE1E2F6CQ37924629-D12388E7-2103-47FD-9208-658389B26D7CQ37974709-6FFEE4CE-C090-4E09-992E-3E42291CDAB6Q38156760-9BEE0FA4-5140-4ECF-A6B7-B1656AC5B076Q38242091-2BDC3B9E-BA00-45CC-B0FC-FF544DE1D786Q38262418-45DB8DAD-5580-448A-8314-523F64D576E7Q38284574-EDE5C5F4-9882-4DA5-B374-F873E6489F57Q38598375-AA72ED6E-EA38-4674-BABE-49C80C58ED05Q38629277-89E1ACA8-2385-429C-BE45-3AAD2CDE7B56Q38841703-02DDF9CE-89F2-4AF8-84B8-B3AF49FEDB29Q39229450-F9ACA06D-5F99-41DE-909C-336373EDC857Q39932241-A5C3D521-A31E-40A6-B511-8932FAD09B63Q42164140-08C9EE2F-27C4-4F33-8551-53B71791A548Q42754446-F8C86C6B-5D2E-45B1-85B1-ACDB95F26E28Q43825518-85BF276F-B017-4141-BC8A-4AACBEFC4C6DQ44237901-2EC22544-9C18-47A8-9BE1-268C2D8DE9B0Q44361036-7E5B855B-42D8-4A6C-9B22-65932A59998DQ44423669-A28A6DAF-65BD-41EF-9887-03BA7BC7FCA3Q46778385-219A2DDF-014E-4AA3-ABB4-8599BF6CB4D3Q47344907-520A9AB4-744B-4765-82CD-8ABFB95251A3Q48121749-D191AA6A-F778-4B92-94CA-1C295BB1F571Q50093660-89DAE3C5-A05C-458C-AD55-EE19FAEA4DE7
P2860
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Relationship among nigrostriat ...... ias in the MPTP primate model.
@en
type
label
Relationship among nigrostriat ...... ias in the MPTP primate model.
@en
prefLabel
Relationship among nigrostriat ...... ias in the MPTP primate model.
@en
P2093
P2860
P1433
P1476
Relationship among nigrostriat ...... ias in the MPTP primate model.
@en
P2093
A M Janson
A McCormack
D A Di Monte
G Petzinger
W J Langston
P2860
P304
P356
10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3
P407
P577
2000-05-01T00:00:00Z